Efficacy and safety of the dual GIP and GLP-1 receptor agonist tirzepatide for weight loss: a meta-analysis of randomized controlled trials

de Mesquita, YLL; Pera Calvi, I; Reis Marques, I; Almeida Cruz, S; Padrao, EMH; Carvalho, PEP; da Silva, CHA; Cardoso, R; Moura, FA; Rafalskiy, VV

doi:10.1038/s41366-023-01337-x

Obesity

Efficacy and safety of the dual GIP and GLP-1 receptor agonist tirzepatide for weight loss: a meta-analysis of randomized controlled trials

Int J Obes (Lond)Published 17 Jul 2023Systematic review and meta-analysis of randomised trials

Read the original article ↗PubMed

Cite

Authors' conclusion

The results support that tirzepatide leads to substantial weight reduction and constitutes a valuable therapeutic option for weight management, despite an increase in gastrointestinal symptoms.

Study context

Population: RCTs of tirzepatide vs placebo, 12 to 72 weeks
Participants: 4,036 participants6 studies

Comparison: Tirzepatide vs placebo
Outcome: Co-primary: absolute and percent change in weight

Pooled result

As reported in the abstract

Body weight (absolute change)

Each group vs placeboMD, kg (95% CI)P value

Tirzepatide 5 mg

−7.7(−11.0 to −4.4)

P < 0.001

Tirzepatide 10 mg

−11.6(−18.8 to −4.3)

P = 0.002

Tirzepatide 15 mg

−11.8(−17.4 to −6.2)

P < 0.001

Further pooled results

Outcome	← Lower vs placebo ←→ Higher vs placebo →	MD (%) (95% CI)	P value
Percent change in weight (co-primary)Tirzepatide 5 mgvs Placebo	−20−10010	−8.1 (−11.0 to −5.2)	P < 0.001
Percent change in weight (co-primary)Tirzepatide 10 mgvs Placebo	−20−10010	−11.9 (−18.1 to −5.6)	P < 0.001
Percent change in weight (co-primary)Tirzepatide 15 mgvs Placebo	−20−10010	−12.4 (−17.2 to −7.5)	P < 0.001
	−20−10010Difference, % (linear scale)

BMI and waist circumference

Tirzepatide also reduced BMI and waist circumference

Safety

Outcome	← Lower odds with tirzepatide 15 mg ←→ Higher odds with tirzepatide 15 mg →	OR (95% CI)	P value
GI adverse events (15 mg dose)Tirzepatide 15 mgvs PlaceboNausea	0.050.21520	4.2 (2.4–7.5)	P < 0.001
GI adverse events (15 mg dose)Tirzepatide 15 mgvs PlaceboVomiting	0.050.21520	7.0 (4.3–11.4)	P < 0.001
GI adverse events (15 mg dose)Tirzepatide 15 mgvs PlaceboDiarrhea	0.050.21520	2.8 (1.6–4.9)	P < 0.001
	0.050.21520Odds ratio (log scale)

Original publication

Efficacy and safety of the dual GIP and GLP-1 receptor agonist tirzepatide for weight loss: a meta-analysis of randomized controlled trials. Int J Obes (Lond). Published 17 July 2023. doi:10.1038/s41366-023-01337-x

Read the original article ↗

Composed by AI from the published abstract and checked against it. How Briefs are made →